These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

533 related articles for article (PubMed ID: 15514571)

  • 41. XIENCE V everolimus-eluting coronary stent system: a novel second generation drug-eluting stent.
    Beijk MA; Piek JJ
    Expert Rev Med Devices; 2007 Jan; 4(1):11-21. PubMed ID: 17187467
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Coronary restenosis after implantation of drug-eluting stents.
    Schofer J; Schlüter M
    Minerva Cardioangiol; 2005 Feb; 53(1):43-8. PubMed ID: 15788978
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Release profiles in drug-eluting stents: issues and uncertainties.
    Venkatraman S; Boey F
    J Control Release; 2007 Jul; 120(3):149-60. PubMed ID: 17582635
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Clinical evidence on polymer-based sirolimus and paclitaxel eluting stents.
    Iijima R; Mehilli J; Schömig A; Kastrati A
    Minerva Cardioangiol; 2006 Oct; 54(5):539-55. PubMed ID: 17019392
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Drug eluting stents in acute myocardial infarction.
    Presbitero P; Boccuzzi G; Pagnotta P
    Panminerva Med; 2005 Jun; 47(2):93-7. PubMed ID: 16210994
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Clinical experiences using everolimus-eluting stents in patients with coronary artery disease.
    Störger H; Grube E; Hofmann M; Schwarz F; Haase J
    J Interv Cardiol; 2004 Dec; 17(6):387-90. PubMed ID: 15546290
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Emerging drugs for coronary restenosis: the role of systemic oral agents the in stent era.
    Rodriguez AE
    Expert Opin Emerg Drugs; 2009 Dec; 14(4):561-76. PubMed ID: 19712016
    [TBL] [Abstract][Full Text] [Related]  

  • 48. [Drug-eluting stents do they make the difference? ].
    Presbitero P; Asioli M
    Minerva Cardioangiol; 2002 Oct; 50(5):431-42. PubMed ID: 12384625
    [TBL] [Abstract][Full Text] [Related]  

  • 49. A comparison of clinical and angiographic outcomes after Excel bioabsorbable polymer versus Firebird durable polymer rapamycin-eluting stent for the treatment of coronary artery disease in a "real world" setting: six-month follow-up results.
    Liu HB; Xu B; Qiao SB; Yang YJ; Ma WH; Qin XW; Yao M; Wu YJ; Yuan JQ; Chen J; You SJ; Dai J; Xia R; Li JJ; Chen JL; Gao RL
    Chin Med J (Engl); 2007 Apr; 120(7):574-7. PubMed ID: 17442205
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Outcome of percutaneous hybrid coronary revascularization: bare metal stents jeopardize the benefit of sirolimus-eluting stents in the real world.
    Fineschi M; Gori T; Pierli C; Casini S; Sinicropi G; Buti A; Del Pasqua A; Bravi A
    Can J Cardiol; 2005 Dec; 21(14):1281-5. PubMed ID: 16341297
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Predictive factors of restenosis after coronary implantation of sirolimus- or paclitaxel-eluting stents.
    Kastrati A; Dibra A; Mehilli J; Mayer S; Pinieck S; Pache J; Dirschinger J; Schömig A
    Circulation; 2006 May; 113(19):2293-300. PubMed ID: 16682614
    [TBL] [Abstract][Full Text] [Related]  

  • 52. A meta-analysis of 16 randomized trials of sirolimus-eluting stents versus paclitaxel-eluting stents in patients with coronary artery disease.
    Schömig A; Dibra A; Windecker S; Mehilli J; Suárez de Lezo J; Kaiser C; Park SJ; Goy JJ; Lee JH; Di Lorenzo E; Wu J; Jüni P; Pfisterer ME; Meier B; Kastrati A
    J Am Coll Cardiol; 2007 Oct; 50(14):1373-80. PubMed ID: 17903638
    [TBL] [Abstract][Full Text] [Related]  

  • 53. A stent is not just a stent: Stent construction and design do matter in its clinical performance.
    Lau KW; Johan A; Sigwart U; Hung JS
    Singapore Med J; 2004 Jul; 45(7):305-11; quiz 312. PubMed ID: 15221045
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Coronary bifurcation stenting. Current techniques, outcome and possible future developments.
    Melikian N; Airoldi F; Di Mario C
    Minerva Cardioangiol; 2004 Oct; 52(5):365-78. PubMed ID: 15514572
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Polymer-free sirolimus-eluting versus polymer-based paclitaxel-eluting stents: an individual patient data analysis of randomized trials.
    Cassese S; Desch S; Kastrati A; Byrne RA; King L; Tada T; Lauer B; Schömig A; Thiele H; Pache J
    Rev Esp Cardiol (Engl Ed); 2013 Jun; 66(6):435-42. PubMed ID: 24776045
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Drug-eluting stent versus bare-metal stent in acute ST-segment elevation myocardial infarction: a word of caution.
    Gupta M; Budoff MJ
    J Invasive Cardiol; 2010 Apr; 22(4):159-60. PubMed ID: 20351385
    [No Abstract]   [Full Text] [Related]  

  • 57. Could Paclitaxel-eluting stents be superior to sirolimus-eluting stents for the treatment of saphenous vein graft lesions?
    Brilakis ES; Banerjee S
    Am J Cardiol; 2010 Nov; 106(9):1367-8. PubMed ID: 21029842
    [No Abstract]   [Full Text] [Related]  

  • 58. [State of treatment of coronary artery disease by drug releasing stents].
    Müller R; Büllesfeld L; Gerckens U; Grube E
    Herz; 2002 Sep; 27(6):508-13. PubMed ID: 12378395
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Classification and current treatment options of in-stent restenosis. Present status and future perspectives.
    Ong AT; Aoki J; McFadden EP; Serruys PW
    Herz; 2004 Mar; 29(2):187-94. PubMed ID: 15057440
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Drug-eluting stents and glycoprotein IIb/IIIa inhibitors: combination therapy for the future.
    Leon MB; Bakhai A;
    Am Heart J; 2003 Oct; 146(4 Suppl):S13-7. PubMed ID: 14564301
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 27.